p-methoxybenzenesulfonic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: p-methoxybenzenesulfonic acid
• 英文别名: 4-Methoxy-bezolsulfinsaeure；p-Methoxybenzolsulfinsaeure；(4-methoxyphenyl)-dioxo-λ6-sulfane
• 化学式: C₇H₈O₃S
• 分子量: 172.205
• InChiKey: XUNSZADDFLWFOL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.67
• 重原子数：
  11.0
• 可旋转键数：
  2.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  43.37
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  p-methoxybenzenesulfonic acid 、 N-morpholino-1-(p-tolyl)methanimine 在 氧气 作用下， 以 乙腈 为溶剂， 反应 10.0h， 以88%的产率得到N-((4-methoxyphenyl)sulfonyl)-4-methyl-N-morpholinobenzamide
  参考文献：
  名称：

  oxy引发的双氧引发的磺酰化反应。

  摘要：

  已经开发了一种简单高效的方法，在室温下无金属条件下，使用亚磺酸作为磺酰基的来源，使用氧气作为绿色氧化剂，对醛衍生的azo酮进行羰基磺酰化。目前的C-O和N-S键形成双官能化策略可提供高收率的各种官能化N-酰基磺酰胺。实验结果表明本反应的根本机理途径。

  DOI：

  10.1021/acs.orglett.0c00759
• 作为产物：
  描述：

  对甲苯磺酰氯 在 sodium tetrahydroborate 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以5.2%的产率得到4,4'-二甲氧基二苯二硫
  参考文献：
  名称：

  Nose, Atsuko; Kudo, Tadahiro, Chemical and pharmaceutical bulletin, 1987, vol. 35, # 5, p. 1770 - 1776

  摘要：

  DOI：

文献信息

• [EN] SMALL MOLECULE DIRECT INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION<br/>[FR] INHIBITEURS DIRECTS À PETITES MOLÉCULES D'INTERACTION PROTÉINE-PROTÉINE DE KEAP1-NRF2
  申请人：UNIV RUTGERS

  公开号：WO2020150446A1

  公开（公告）日：2020-07-23

  This patent document diclsoes novel compounds and methods of preventing or treating diseases or conditions related to Keapl-Nrf2 interaction activity by use of the novel compounds. As direct inhibitors of Keapl-Nrf2 interaction, the compounds disclosed herein are more specific and free of various undesirable effects than existing indirect inhibitors, and are potential dmg candidates of chemopreventive and therapeutic agents for treatment of various diseases or conditions involving oxidative stress and/or inflammation, including but not limited to cancers, diabetes, Alzheimer's, Parkinson's, and inflammatory bowel disease including ulcerative colitis.

  这项专利文件披露了一种新颖的化合物和方法，通过使用这些新颖的化合物来预防或治疗与Keapl-Nrf2相互作用活性相关的疾病或状况。作为Keapl-Nrf2相互作用的直接抑制剂，本文披露的化合物比现有的间接抑制剂更具特异性，且不受各种不良影响，是潜在的化学预防和治疗剂的候选人，用于治疗涉及氧化应激和/或炎症的各种疾病或状况，包括但不限于癌症、糖尿病、阿尔茨海默病、帕金森病和溃疡性结肠炎等。
• [EN] PERIPHERAL ALKYL AND ALKENYL CHAINS EXTENDED BENZENE DERIVATIVES AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME<br/>[FR] DÉRIVÉS BENZÉNIQUES À CHAÎNES ALKYLE ET ALCÉNYLE PÉRIPHÉRIQUES ÉTENDUES ET COMPOSITION PHARMACEUTIQUE COMPRENANT CEUX-CI
  申请人：TAIWANJ PHARMACEUTICALS CO LTD

  公开号：WO2020205455A1

  公开（公告）日：2020-10-08

  The compounds represented by Formula (I), which are peripheral alkyl and alkenyl chains extended benzene derivatives, are useful as dual autotaxin (ATX) / histone deacetylase (HD AC) inhibitors. These compounds may be included in a pharmaceutical composition along with a pharmaceutically acceptable carrier, and be used in a therapeutically effective amount for prophylaxis or treatment of various diseases and disorders.

  由公式（I）代表的化合物是外周烷基和烯基链延伸的苯衍生物，可作为双重自动税林(ATX) / 组蛋白去乙酰化酶(HDAC)抑制剂而有用。这些化合物可以与药学上可接受的载体一起组成药物组合物，并以治疗有效量用于预防或治疗各种疾病和疾病。
• [EN] THIENOISOQUINOLINES AND THEIR DERIVATIVES FOR THE TREATMENT OF CANCER<br/>[FR] THIÉNOISOQUINOLÉINES ET LEURS DÉRIVÉS POUR LE TRAITEMENT DU CANCER
  申请人：VALORBEC SEC

  公开号：WO2018102920A1

  公开（公告）日：2018-06-14

  The present disclosure relates to fused N-arylsulfonamidyl-thienoisoquinoline compounds, derivatives and pharmaceutical compositions thereof, and methods and uses in inhibiting cancer cell growth, along with a supplemental anti-cancer agent. Centrosome targeting and microtubule depolymerisation are attractive in designing the present chemotherapeutic compounds. The various diseases and conditions treated include various types of cell cancers, and in vitro inhibition.

  本公开涉及融合的N-芳基磺胺基噻吩异喹啉化合物，其衍生物和药物组合物，以及在抑制癌细胞生长方面的方法和用途，以及辅助抗癌药物。针对中心粒和微管去聚合是设计目前化疗化合物的吸引点。治疗的各种疾病和病况包括各种类型的细胞癌和体外抑制。
• [EN] OXIME SULFONATE DERIVATIVES<br/>[FR] DÉRIVÉS DE SULFONATE D'OXIME
  申请人：BASF SE

  公开号：WO2016030790A1

  公开（公告）日：2016-03-03

  Oxime sulfonate compounds of the formula (I), wherein R 1 is O(CO)R 4, COOR 5 or CONR 6R 7; n is 1 or 2; R 2 for example is C 1-C 8alkyl, C 3-C 6cycloalkyl or benzyl; R 3 is for example C 1-C 8alkyl, C 3-C 6cycloalkyl, C 1-C 8haloalkyl, C 2-C 8alkenyl, benzyl, phenyl or naphthyl, which optionally are substituted; R 4 is for example C 1-C 8alkyl, C 3-C 6cycloalkyl, C 1-C 8haloalkyl, C 2-C 8alkenyl, benzyl, phenyl or naphthyl, which optionally are substituted; R 5 is for example C 3-C 20alkyl, C 3-C 14cycloalkyl, C 2-C 8alkenyl, C 1-C 12alkyl which is substituted for example by one or more halogen; or R 5 is phenyl or naphthyl, which are unsubstituted; R 6 and R 7 each independently of one another for example are hydrogen, C 1-C 12alkyl, C 1-C 4haloalkyl, phenyl-C 1-C 4alkyl, C 2-C 8alkenyl or C 3-C 6cycloalkyl, phenyl or naphthyl; or R 6 and R 7, together with the N-atom to which they are attached, form a 5- or 6-membered ring; are suitable as thermal radical initiators.

  化合物的氧肟磺酸盐，其化学式为（I），其中R1为O（CO）R4，COOR5或CONR6R7; n为1或2; R2例如为C1-C8烷基，C3-C6环烷基或苄基; R3例如为C1-C8烷基，C3-C6环烷基，C1-C8卤代烷基，C2-C8烯基，苄基，苯基或萘基，可以选择性地被取代; R4例如为C1-C8烷基，C3-C6环烷基，C1-C8卤代烷基，C2-C8烯基，苄基，苯基或萘基，可以选择性地被取代; R5例如为C3-C20烷基，C3-C14环烷基，C2-C8烯基，C1-C12烷基，例如被一个或多个卤素取代; 或者R5是未被取代的苯基或萘基; R6和R7各自独立地例如为氢，C1-C12烷基，C1-C4卤代烷基，苯基-C1-C4烷基，C2-C8烯基或C3-C6环烷基，苯基或萘基; 或者R6和R7与它们所连接的N原子一起形成一个5-或6-成员环; 适用于热引发自由基反应剂。
• [EN] ANTIFUNGAL AGENTS<br/>[FR] AGENTS ANTIFONGIQUES
  申请人：MERCK & CO INC

  公开号：WO2009045311A1

  公开（公告）日：2009-04-09

  Novel derivatives of enfumafungin are disclosed herein, along with their, pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antifungal agents and/or inhibitors of (l,3)-β-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating and/or preventing fungal infections and associated diseases and conditions.

  本文披露了恩福马富金的新衍生物，以及它们的药物可接受的盐、水合物和前药。还披露了包含这些化合物的组合物，制备这些化合物的方法以及将这些化合物用作抗真菌剂和/或(1,3)-β-D-葡聚糖合成酶抑制剂的方法。这些披露的化合物、它们的药物可接受的盐、水合物和前药，以及包含这些化合物、盐、水合物和前药的组合物，有助于治疗和/或预防真菌感染及相关疾病和症状。